| Replimune (REPL) Gains on Positive Data From Melanoma Study | 06/07 10:05 | zacks.com |
| Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference | 06/07 08:00 | globenewswire.com |
| Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma | 06/06 07:00 | globenewswire.com |
| Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | 06/03 08:00 | globenewswire.com |
| Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | 05/23 17:00 | globenewswire.com |
| Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update | 05/16 08:00 | globenewswire.com |
| Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting | 04/07 17:00 | globenewswire.com |
| Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 04/04 08:00 | globenewswire.com |
| Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions | 03/26 07:30 | globenewswire.com |
| How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17% | 03/11 10:56 | zacks.com |